The MAESTRO registry is a post-market, single-arm, non-interventional, multicenter registry
Patient, or another authorized person as per country-specific regulations, is informed of the data collection and gives non-opposition or consent prior to the data collection in accordance with institutional and geographic requirements.
For Cohort 1, patient is treated for a ruptured or unruptured intracranial aneurysm using a commercially available MicroVention implant device as the primary treatment device and the decision to use this device has been made by the treating physician outside the context of the MAESTRO study.
For Cohort 2, patient is treated using a commercially available MicroVention mechanical thrombectomy device as the first-line treatment strategy and the decision to use this device has been made by the treating physician outside the context of the MAESTRO study.
Patient is or is expected to be inaccessible for follow-up.
Patient is participating or intends to participate in another study that changes the site practice.
Patient is already participating in the MAESTRO study for the same pathology.
Microvention-Terumo, Inc.
Lead sponsor